Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Orbital inflammation after zoledronate infusion: an emerging complication.

Rahimy E, Law SK.

Can J Ophthalmol. 2013 Feb;48(1):e11-2. doi: 10.1016/j.jcjo.2012.09.011. No abstract available.

PMID:
23419305
2.

Zoledronic acid infusion and orbital inflammatory disease.

Sharma NS, Ooi JL, Masselos K, Hooper MJ, Francis IC.

N Engl J Med. 2008 Sep 25;359(13):1410-1. doi: 10.1056/NEJMc0803366. No abstract available.

3.

Bisphosphonate-associated orbital inflammation--a case report and review.

Peterson JD, Bedrossian EH Jr.

Orbit. 2012 Apr;31(2):119-23. doi: 10.3109/01676830.2011.648818. Review.

PMID:
22489855
4.

Orbital inflammatory disease after intravenous infusion of zoledronate for treatment of metastatic renal cell carcinoma.

Phillips PM, Newman SA.

Arch Ophthalmol. 2008 Jan;126(1):137-9. doi: 10.1001/archophthalmol.2007.17. No abstract available.

PMID:
18195236
5.

Bisphosphonate-Induced Orbital Inflammation: A Case Series and Review.

Pirbhai A, Rajak SN, Goold LA, Cunneen TS, Wilcsek G, Martin P, Leibovitch I, Selva D.

Orbit. 2015;34(6):331-5. doi: 10.3109/01676830.2015.1078380. Epub 2015 Nov 5. Review.

PMID:
26540241
6.

Bisphosphonate-induced orbital inflammation.

Mbekeani JN, Slamovits TL.

J Neuroophthalmol. 2010 Jun;30(2):205-6; author reply 206. doi: 10.1097/WNO.0b013e3181e08c3e. No abstract available.

PMID:
20523198
7.

Orbital inflammatory disease in a patient treated with zoledronate.

Kaur H, Uy C, Kelly J, Moses AM.

Endocr Pract. 2011 Jul-Aug;17(4):e101-3. doi: 10.4158/EP11081.CR.

PMID:
21803720
8.

A Case Series and Review of Bisphosphonate-associated Orbital Inflammation.

Lefebvre DR, Mandeville JT, Yonekawa Y, Arroyo JG, Torun N, Freitag SK.

Ocul Immunol Inflamm. 2016;24(2):134-9. doi: 10.3109/09273948.2014.942747. Epub 2014 Aug 25. Review.

PMID:
25153041
9.

Orbital Inflammation Secondary to Zoledronic Acid, a Rare Presentation.

Muruganandam M, Sandhu H.

J Clin Rheumatol. 2016 Oct;22(7):384. doi: 10.1097/RHU.0000000000000433. No abstract available.

PMID:
27488454
10.

A once-yearly IV bisphosphonate for osteoporosis.

[No authors listed]

Obstet Gynecol. 2008 May;111(5):1208-9. doi: 10.1097/01.AOG.0000313748.64874.e8. No abstract available.

PMID:
18448761
11.

Zoledronate Induced Hypocalcemia and Hypophosphatemia in Osteoporosis: A Cause of Concern.

Kaur U, Chakrabarti SS, Gambhir IS.

Curr Drug Saf. 2016;11(3):267-9.

PMID:
27113952
12.

[Inflammation of the jaws during treatment with bisphosphonates].

Bartl R.

Dtsch Med Wochenschr. 2011 Oct;136(41):2109-10. doi: 10.1055/s-0031-1292022. Epub 2011 Oct 4. German. No abstract available.

PMID:
21971888
13.

Zolendronate associated inflammatory orbital disease.

Yeo J, Jafer AK.

N Z Med J. 2010 Sep 24;123(1323):50-2.

PMID:
20930911
14.

Acute anterior uveitis following zoledronic acid infusion for osteoporosis.

Belliveau MJ, Almeida DR, Urton TE.

Can J Ophthalmol. 2012 Oct;47(5):e22-3. doi: 10.1016/j.jcjo.2012.03.020. Epub 2012 Jul 11. No abstract available.

PMID:
23036555
15.

Bisphosphonates, as a new cause of drug-induced jaw osteonecrosis: an update.

Jimenez-Soriano Y, Bagan JV.

Med Oral Patol Oral Cir Bucal. 2005 Jul 1;10 Suppl 2:E88-91. English, Spanish. No abstract available.

16.

Giant cell arteritis with visual loss following zoledronic acid infusion.

Metyas S, Ibrahim M, Solyman J, Yeter KC, Arkfeld DG.

Int J Rheum Dis. 2014 Jan;17(1):113-5. doi: 10.1111/1756-185X.12263. Epub 2013 Dec 13.

PMID:
24472274
17.

Zoledronate-related osteonecrosis of the mandible.

Ho L, Quan V, Henderson R.

Clin Nucl Med. 2008 Jan;33(1):68-70.

PMID:
18097268
18.
19.

Consultation corner. Bone loss drug gives users a break.

Bellantoni M.

Johns Hopkins Med Lett Health After 50. 2007 Dec;19(10):6. No abstract available.

PMID:
18225340
20.

Nitrogen bisphosphonate-induced orbital inflammatory disease: gamma delta T cells--a report and review of 2 cases.

Vora MM, Rodgers IR, Uretsky S.

Ophthal Plast Reconstr Surg. 2014 Jul-Aug;30(4):e84-5. doi: 10.1097/IOP.0b013e31829f3b46. Review.

PMID:
24814269

Supplemental Content

Support Center